Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
The Food and Drug administration is moving a step closer to three major Covid vaccine decisions — Novavax, shots for kids under 5, and a redesigned vaccine to target new variants.
The FDA committee will meet in June to review those issues, and its
recommendations will weigh heavily on whether the vaccines are authorized or not.
Parents have been waiting for months to have an option to vaccinate kids under age 5, the only group left in the U.S. not yet eligible. People who want an alternative to Pfizer and Moderna's vaccines for adults have been calling on the FDA to authorize Novavax's shots, which use more traditional protein technology.
However, the biggest decision the FDA will take is whether to redesign the vaccines to target mutations on the virus to boost protection. The clock is ticking as epidemiologists expect another wave of infection in the fall. The FDA still has to get all the vaccine companies on the same page to make sure they're choosing the right formulas.
Pfizer and Moderna are working on shots that would target the omicron variant as well as the original Wuhan strain. The CDC this week revealed just how vast the omicron wave was, with nearly 60% of Americans having antibodies from infection as of February.
Feel free to send any tips, suggestions, story ideas and data in the meantime to me at spencer.kimball@nbcuni.com.
Tidak ada komentar:
Posting Komentar